 |
 |
 |
 |
 |
 |
 |
 |
-
BROWSE TOPICS IN CLINICAL MANAGEMENT:
Antiretroviral Therapy- Complications of HIV/HAART
- Research & Development
- Clinical Trials
- Quality of Life & Patient Care
Antiretroviral Therapy
Enfuvirtide (T-20, Fuzeon)
The Basics
- A Clinical Overview of Enfuvirtide (T-20, Fuzeon) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health - Characteristics of Fusion and Integrase Inhibitors, and CCR5 Antagonists (PDF) (January 29, 2008)
An excerpt from the official U.S. HIV treatment guidelines for adults and adolescents. For the full guidelines, click here (PDF).
From AIDSinfo - Important Changes to Fuzeon Product Labeling (January 31, 2007)
From U.S. Food and Drug Administration - Prescribing Information for Enfuvirtide (T-20, Fuzeon) (PDF) (January 2007)
From Roche - A Guide to Fuzeon: The First Fusion Inhibitor (January 2005)
To read PDF, click here
In A Guide to Fuzeon: The First Fusion Inhibitor, from The Body - Fuzeon -- A Review of the First Entry Inhibitor (October 2003)
A look at how entry inhibitors and Fuzeon work.
To read PDF, click here
From The Body - FDA Approves Enfuvirtide (Fuzeon, ENF, T-20), the First HIV Fusion Inhibitor (May 2003)
A review of current knowledge regarding T-20 access and administration and optimal use guidelines, as well as a quick profile of the drug.
In Hopkins HIV Report - Fuzeon (T-20) Approved in the U.S. (March 13, 2003)
First drug in a new class of HIV/AIDS treatments for HIV-infected adults and children with advanced HIV infection.
From U.S. Food and Drug Administration - Long Path to Approval (March 2003)
A look back at Fuzeon's road from laboratory to pharmacy.
In GMHC Treatment Issues, from Gay Men's Health Crisis
  |
  |